Abstract
Sabril (vigabatrin) oral solution was approved by the FDA on August 21st, 2009 for treatment of infantile spasms in children ages 1 month to 2 years and complex partial seizures in adults (tablets).
MeSH terms
-
4-Aminobutyrate Transaminase / antagonists & inhibitors
-
Anticonvulsants / adverse effects
-
Anticonvulsants / chemistry*
-
Anticonvulsants / pharmacology
-
Anticonvulsants / therapeutic use
-
Clinical Trials as Topic
-
Double-Blind Method
-
Enzyme Inhibitors / chemistry
-
Enzyme Inhibitors / pharmacology
-
Enzyme Inhibitors / therapeutic use
-
Epilepsy / drug therapy
-
Epilepsy / enzymology
-
Humans
-
Molecular Structure
-
Multicenter Studies as Topic
-
Randomized Controlled Trials as Topic
-
Single-Blind Method
-
Vigabatrin / adverse effects
-
Vigabatrin / chemistry*
-
Vigabatrin / pharmacology
-
Vigabatrin / therapeutic use
-
Vision Disorders / chemically induced
Substances
-
Anticonvulsants
-
Enzyme Inhibitors
-
4-Aminobutyrate Transaminase
-
Vigabatrin